PB2230: EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT

• M. Karimi,
• T. Zarei,
• S. Haghpanah,
• A. Azarkeivan,
• M. Naderi,
• S. Matin,
• A. Bazrafshan,
• Z. Zahedi,
• A. Shirkavand,
• P. Pishdad,
• V. De Sanctis

Affiliations

M. Karimi

1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz

T. Zarei

1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz

S. Haghpanah

1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz

A. Azarkeivan

2 Zafar Adult Thalassemia Clinic, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine

M. Naderi

3 Iranian Blood Transfusion Organization Research Center, Thalassemia Clinic, Tehran

S. Matin

4 Pediatric Department, Jahrom University of Medical Sciences, Jahrom

A. Bazrafshan

1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz

Z. Zahedi

1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz

A. Shirkavand

5 Laser Medicine Research group, MLRC, Yara institute, ACECR; Medical physicist, Pardis Noor Medical Imaging center, Tehran

P. Pishdad

6 Medical Imaging Research Center, Department of Radiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

V. De Sanctis

7 Coordinator of ICET-A Network (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine) and Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy